English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Prophylaxis and treatment with factor replacement have greatly improved the quality of care forpatients with hemophilia.However, development of factor inhibitors is the most serious and challengingcomplication of therapy. Other complications are viral infections like Hepatitis B, Hepatitis C, and HIV,and the other infective diseases, which can be transmitted by the blood and blood products transfusion.The aims of this study is to study the complications in the hemophiliacs who have been treatedprophylactically or ‘on demand’ with fresh frozen plasma, cryoprecipitate and concentrated products ofFVIII andDuring the study period, all patients (100) with Hemophilia attending Gandhi Medical College are takenunder consideration. The presence of an inhibitor was determined by a simple mixing experiment using thetest plasma and normal pooled plasma and 3rd generation enzyme linked immunosorbent assay (ELISA)method& anti-HBsAg.statisticalThe inhibitor study showed that in 7%(3.2-13.98 at 95% confidence interval) patients, APTT was notcorrected after mixing patients plasma with pooled normal plasma (PNP) and applying the test immediatelyand after one hour of incubation. serological tests showed antibodies for HCV were positive in 4% of cases(1.1%-9.93% at 95% CI), whereas antibodies against HBsAg was positive in 1% of cases(0.3%-5.45% at95% CI), which was less then anti HCV. Transfusion associated complications were higher in severe formof Haemophilia as compared to moderate and mild form of Hemophilia.Developing antibodies to infused factor concentrates (inhibitors) remains a major source of morbidity andmortality in the treatment of patients with hemophilia. Novel treatment approaches for these patients arein developmental stage, which include therapeutic agents that mimic factor VIII or augment thrombinproduction by bypassing the inhibitors, as well as agents that act by inhibiting the natural anticoagulants.Keywords: Activated partial thrombopla

A study in respect of transfusion related complications in hemophiliacs with special reference to developing factor inhibitors